Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

NCT: NCT05102019 · RECRUITING

NCT IDNCT05102019
StatusRECRUITING
Start Date2022-01-04
Completion2032-01

Brief Summary

To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm registry will further assess the safety and effectiveness of the Shockwave Reducer in selected subjects with reversible myocardial ischemia in the distribution of the right coronary artery and who are deemed unsuitable for revascularization, subjects without documented obstructive coronary disease and abnormal coronary flow reserve (ANOCA), and subjects who cannot complete an exercise tolerance test due to lower limb amputation (above the ankle) or other physiologic condition with documented chronic mobility or balance issues that require the use of a walking aid.

Frequently Asked Questions

What is Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II?

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II is a clinical trial registered under NCT05102019. Current status: RECRUITING.

What is the status of NCT05102019?

The current status of NCT05102019 (Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II) is: RECRUITING.

When did Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II start?

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II started on 2022-01-04.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.